These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 32617743)

  • 61. [The molecular genetics of meningiomas and genotypic/phenotypic correlations].
    Dezamis E; Sanson M
    Rev Neurol (Paris); 2003 Sep; 159(8-9):727-38. PubMed ID: 13679715
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mutational signature of extracranial meningioma metastases and their respective primary tumors.
    Biczok A; Thorsteinsdottir J; Karschnia P; Ruf VC; Tonn JC; Herms J; Schichor C; Dorostkar MM
    Acta Neuropathol Commun; 2023 Jan; 11(1):12. PubMed ID: 36641486
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Meningioma].
    Sasaki H
    No Shinkei Geka; 2023 Sep; 51(5):829-836. PubMed ID: 37743334
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Current Status of Genetic/Molecular Abnormality Analysis and Prognosis Prediction of Meningioma].
    Okano A
    No Shinkei Geka; 2024 Jul; 52(4):718-724. PubMed ID: 39034510
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pediatric clear cell meningioma involving the middle cranial fossa in the context of NF2 and SMARCE1 mutations.
    Libert DM; Prayson RA
    Ann Diagn Pathol; 2020 Jun; 46():151516. PubMed ID: 32311644
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mutational analysis of the NF2 gene in sporadic meningiomas by denaturing high-performance liquid chromatography.
    Kim JH; Kim IS; Kwon SY; Jang BC; Suh SI; Shin DH; Jeon CH; Son EI; Kim SP
    Int J Mol Med; 2006 Jul; 18(1):27-32. PubMed ID: 16786152
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A.
    Nakane Y; Natsume A; Wakabayashi T; Oi S; Ito M; Inao S; Saito K; Yoshida J
    J Neurosurg; 2007 Aug; 107(2):398-404. PubMed ID: 17695396
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [The Potential of Personalized/Precision Medicine for Meningiomas].
    Yamaguchi S; Fujimura M
    No Shinkei Geka; 2022 Jan; 50(1):132-140. PubMed ID: 35169093
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A Rapid Robust Method for Subgrouping Non-NF2 Meningiomas According to Genotype and Detection of Lower Levels of M2 Macrophages in
    Adams CL; Ercolano E; Ferluga S; Sofela A; Dave F; Negroni C; Kurian KM; Hilton DA; Hanemann CO
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32070062
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Molecular and Immunological Landscape of Meningiomas.
    Lotsch C; Warta R; Herold-Mende C
    Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273576
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
    Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
    Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Meningioma: an update.
    Lusis E; Gutmann DH
    Curr Opin Neurol; 2004 Dec; 17(6):687-92. PubMed ID: 15542977
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Genomic landscape of intracranial meningiomas.
    Bi WL; Abedalthagafi M; Horowitz P; Agarwalla PK; Mei Y; Aizer AA; Brewster R; Dunn GP; Al-Mefty O; Alexander BM; Santagata S; Beroukhim R; Dunn IF
    J Neurosurg; 2016 Sep; 125(3):525-35. PubMed ID: 26771848
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Genomic profile of human meningioma cell lines.
    Mei Y; Bi WL; Greenwald NF; Agar NY; Beroukhim R; Dunn GP; Dunn IF
    PLoS One; 2017; 12(5):e0178322. PubMed ID: 28552950
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms.
    Pham MH; Zada G; Mosich GM; Chen TC; Giannotta SL; Wang K; Mack WJ
    Neurosurg Focus; 2011 May; 30(5):E7. PubMed ID: 21529178
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications.
    Robert SM; Vetsa S; Nadar A; Vasandani S; Youngblood MW; Gorelick E; Jin L; Marianayagam N; Erson-Omay EZ; Günel M; Moliterno J
    J Neurooncol; 2022 Jan; 156(2):205-214. PubMed ID: 34846640
    [TBL] [Abstract][Full Text] [Related]  

  • 77. DNA methylation profiling of meningiomas highlights clinically distinct molecular subgroups.
    Singh J; Sharma R; Shukla N; Narwal P; Katiyar A; Mahajan S; Sahu S; Garg A; Sharma MC; Suri A; Sarkar C; Suri V
    J Neurooncol; 2023 Jan; 161(2):339-356. PubMed ID: 36564673
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evolving concepts in meningioma management in the era of genomics.
    Hsieh AL; Bi WL; Ramesh V; Brastianos PK; Plotkin SR
    Cancer; 2024 Aug; 130(15):2586-2600. PubMed ID: 38753473
    [TBL] [Abstract][Full Text] [Related]  

  • 79. An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas.
    Sun SQ; Hawasli AH; Huang J; Chicoine MR; Kim AH
    Neurosurg Focus; 2015 Mar; 38(3):E3. PubMed ID: 25727225
    [TBL] [Abstract][Full Text] [Related]  

  • 80. hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas.
    Fürtjes G; Köchling M; Peetz-Dienhart S; Wagner A; Heß K; Hasselblatt M; Senner V; Stummer W; Paulus W; Brokinkel B
    J Neurooncol; 2016 Oct; 130(1):79-87. PubMed ID: 27465278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.